#1 Clinical Trials Search in Europe

2-[[5-[3-[[6-[[(5S)-5-Carboxy-5-[[(1S)-1,3-Dicarboxypropyl]Carbamoylamino]Pentyl]Amino]-6-Oxohexyl]Amino]-3-Oxopropyl]-2-Oxidophenyl]Methyl-[2-[[5-(2-Carboxyethyl)-2-Oxidophenyl]Methyl-(Carboxylatomethyl)Amino]Ethyl]Amino]Acetate:gallium-68(3+) Hydron

This article discusses clinical trials investigating the use of 68Ga-PSMA, a radioactive imaging agent, in patients with high-risk prostate cancer. These studies aim to improve the detection of lymph node metastases and guide surgical decisions for prostate cancer patients. The trials focus on evaluating the effectiveness of 68Ga-PSMA PET/CT imaging in assessing lymph node involvement before surgery and its potential impact on treatment strategies.

Table of Contents

What is 68Ga-PSMA?

68Ga-PSMA is a diagnostic tool used in the detection and management of prostate cancer. The full name of this compound is quite complex: 2-[[5-[3-[[6-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-6-oxohexyl]amino]-3-oxopropyl]-2-oxidophenyl]methyl-[2-[[5-(2-carboxyethyl)-2-oxidophenyl]methyl-(carboxylatomethyl)amino]ethyl]amino]acetate:gallium-68(3+) hydron. It’s also known by the simpler name 68Ga-PSMA HBED-CC.[1]

How does it work?

68Ga-PSMA is a radioactive tracer that binds to a protein called Prostate-Specific Membrane Antigen (PSMA). This protein is found in high amounts on prostate cancer cells. When injected into the body, the 68Ga-PSMA attaches to these cancer cells, making them visible during a special type of scan called a PET/CT (Positron Emission Tomography/Computed Tomography).[2]

Uses in Prostate Cancer

68Ga-PSMA is primarily used for:

  • Detecting prostate cancer that has spread to lymph nodes or other parts of the body
  • Helping doctors plan surgery or other treatments
  • Monitoring how well treatment is working

It’s particularly useful in patients with intermediate or high-risk prostate cancer, where there’s a higher chance that the cancer may have spread beyond the prostate.[3]

Administration and Dosage

68Ga-PSMA is given as an intravenous injection, which means it’s injected directly into a vein. The dose is usually calculated based on the patient’s weight, with a typical dose being around 5 MBq (megabecquerels) per kilogram of body weight. The injection is usually given about an hour before the PET/CT scan.[2][3]

Ongoing Clinical Trials

Several clinical trials are currently underway to further investigate the use of 68Ga-PSMA in prostate cancer management:

  1. A study is looking at how well 68Ga-PSMA PET/CT can detect lymph node metastases in patients with intermediate or high-risk prostate cancer before they undergo surgery.[3]
  2. Another trial is investigating the use of 68Ga-PSMA in combination with a drug called pembrolizumab in patients with high-risk prostate cancer.[1]
  3. Researchers are also studying how 68Ga-PSMA imaging can guide surgery to improve the detection of lymph node metastases in prostate cancer patients.[2]

Potential Benefits

The use of 68Ga-PSMA PET/CT imaging may offer several benefits:

  • More accurate detection of cancer spread, especially to lymph nodes
  • Better surgical planning, potentially leading to more precise removal of affected lymph nodes
  • Improved ability to monitor treatment effectiveness
  • Potential to guide more personalized treatment decisions

Safety and Side Effects

68Ga-PSMA appears to be well-tolerated by most patients. One of the ongoing clinical trials aims to confirm the “perfect tolerance” of this compound.[3] However, as with any medical procedure involving radiation, there are some considerations:

  • The radiation exposure is generally considered low and safe
  • Allergic reactions are rare but possible
  • Patients with severely impaired kidney or liver function may need special consideration

It’s important to discuss any concerns or potential risks with your healthcare provider.

Aspect Details
Study Focus Use of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients
Main Objectives Assess accuracy in detecting lymph node metastases, evaluate impact on surgical planning
Target Patients Intermediate to high-risk prostate cancer patients eligible for radical prostatectomy
Imaging Agent 68Ga-PSMA (2-[[5-[3-[[6-[[(5S)-5-CARBOXY-5-[[(1S)-1,3-DICARBOXYPROPYL]CARBAMOYLAMINO]PENTYL]AMINO]-6-OXOHEXYL]AMINO]-3-OXOPROPYL]-2-OXIDOPHENYL]METHYL-[2-[[5-(2-CARBOXYETHYL)-2-OXIDOPHENYL]METHYL-(CARBOXYLATOMETHYL)AMINO]ETHYL]AMINO]ACETATE:GALLIUM-68(3+) HYDRON)
Administration Intravenous injection, doses ranging from 160 MBq to 5 MBq/kg
Primary Endpoints Diagnostic performance in detecting lymph node metastases, impact on surgical strategy
Potential Benefits Improved detection of metastases, better surgical planning, more personalized treatment

FAQ

  • What is 68Ga-PSMA and how is it used in these clinical trials? 68Ga-PSMA is a radioactive imaging agent that targets prostate-specific membrane antigen (PSMA), a protein found in high levels in prostate cancer cells. In these trials, it is used in PET/CT scans to detect lymph node metastases in patients with high-risk prostate cancer before they undergo surgery.
  • Who are the target patients for these clinical trials? The trials primarily focus on patients with intermediate to high-risk prostate cancer who are candidates for radical prostatectomy (surgical removal of the prostate). Typically, these patients have a risk of lymph node invasion greater than 5% based on pre-operative assessments.
  • What are the main objectives of these clinical trials? The main objectives include assessing the accuracy of 68Ga-PSMA PET/CT in detecting lymph node metastases, evaluating its impact on surgical planning, and comparing its performance to conventional imaging methods like MRI.
  • How is 68Ga-PSMA administered to patients in these trials? 68Ga-PSMA is administered to patients through intravenous injection. The typical dose ranges from 160 MBq to 5 MBq/kg, depending on the specific trial protocol.
  • What are the potential benefits of using 68Ga-PSMA imaging in prostate cancer patients? The potential benefits include more accurate detection of lymph node metastases, improved surgical planning for lymph node dissection, and better overall staging of prostate cancer. This could lead to more personalized and effective treatment strategies for patients with high-risk prostate cancer.

Ongoing Clinical Trials on 2-[[5-[3-[[6-[[(5S)-5-Carboxy-5-[[(1S)-1,3-Dicarboxypropyl]Carbamoylamino]Pentyl]Amino]-6-Oxohexyl]Amino]-3-Oxopropyl]-2-Oxidophenyl]Methyl-[2-[[5-(2-Carboxyethyl)-2-Oxidophenyl]Methyl-(Carboxylatomethyl)Amino]Ethyl]Amino]Acetate:gallium-68(3+) Hydron

  • Evaluation of PSMA PET/CT Imaging for Lymph Node Assessment in Patients with Intermediate and High-Risk Non-Metastatic Prostate Cancer Before Surgery

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Pembrolizumab and 68GA-PSMA HBED-CC in Patients with High-Risk Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Imaging-Guided Surgery for Prostate Cancer Patients Using [68Ga]PSMA-HBED-CC and [99mTc]PSMA I&S

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • 68Ga-PSMA: A radioactive imaging agent that targets prostate-specific membrane antigen (PSMA), used in PET/CT scans to detect prostate cancer cells.
  • PET/CT: Positron Emission Tomography/Computed Tomography, an imaging technique that combines PET and CT scans to provide detailed images of the body's structures and functions.
  • Radical Prostatectomy: A surgical procedure to remove the entire prostate gland and surrounding tissues as a treatment for prostate cancer.
  • Lymph Node Invasion (LNI): The spread of cancer cells to the lymph nodes, which can indicate more advanced stages of prostate cancer.
  • Extended Pelvic Lymph Node Dissection (ePLND): A surgical procedure to remove lymph nodes in the pelvic area to check for cancer spread and improve cancer staging.
  • Briganti Nomogram: A tool used to predict the risk of lymph node invasion in prostate cancer patients based on various clinical factors.
  • PSA: Prostate-Specific Antigen, a protein produced by the prostate gland that can be measured in the blood to help detect prostate cancer.
  • ISUP Grade: International Society of Urological Pathology Grade, a system used to classify the aggressiveness of prostate cancer based on biopsy results.
  • Neoadjuvant Therapy: Treatment given before the main treatment (usually surgery) to shrink the tumor or kill cancer cells that may have spread.
  • MBq: Megabecquerel, a unit of measurement for radioactivity used to describe the dose of radioactive tracers like 68Ga-PSMA.

References

  1. http://clinicaltrials.eu/trial/study-of-pembrolizumab-and-68ga-psma-hbed-cc-in-patients-with-high-risk-prostate-cancer/
  2. http://clinicaltrials.eu/trial/study-on-imaging-guided-surgery-for-prostate-cancer-patients-using-68gapsma-hbed-cc-and-99mtcpsma-is/
  3. http://clinicaltrials.eu/trial/study-on-68ga-psma-pet-ct-imaging-for-lymph-node-detection-in-intermediate-and-high-risk-prostate-cancer-patients/